+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastroparesis Drugs - Global Market Trajectory & Analytics

  • ID: 5309459
  • Report
  • April 2021
  • Region: Global
  • 188 pages
  • Global Industry Analysts, Inc
1 of 2
Global Gastroparesis Drugs Market to Reach $7.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Gastroparesis Drugs estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 4.5% over the analysis period 2020-2027. Diabetic Gastroparesis, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$2.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Idiopathic Gastroparesis segment is readjusted to a revised 5.4% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 4.2% CAGR

The Gastroparesis Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Post-Surgical Gastroparesis Segment to Record 3.1% CAGR

In the global Post-Surgical Gastroparesis segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$641.9 Million in the year 2020 will reach a projected size of US$801 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$804.4 Million by the year 2027.

Select Competitors (Total 47 Featured):
  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Cadila Pharmaceuticals Ltd.
  • ETX Pharma, Inc.
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Neurogastrx Inc.
  • Theravance Biopharma, Inc.
  • Valeant Pharmaceuticals International, Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Gastroparesis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Gastroparesis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Gastroparesis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Diabetic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Diabetic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Diabetic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Idiopathic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Idiopathic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Idiopathic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Post-Surgical Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Post-Surgical Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Post-Surgical Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 25: World Current & Future Analysis for E-Commerce by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 26: World Historic Review for E-Commerce by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: World 15-Year Perspective for E-Commerce by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 28: USA Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: USA Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: USA 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 31: USA Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: USA Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: USA 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 34: Canada Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Canada Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Canada 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 37: Canada Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Canada Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Canada 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 40: Japan Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Japan Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Japan 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 43: Japan Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Japan Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Japan 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 46: China Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: China Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: China 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 49: China Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: China Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: China 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 52: Europe Current & Future Analysis for Gastroparesis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Gastroparesis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Gastroparesis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 55: Europe Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Europe Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Europe 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 58: Europe Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: Europe Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: Europe 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 61: France Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: France Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 63: France 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 64: France Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: France Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 66: France 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 67: Germany Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Germany Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 69: Germany 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 70: Germany Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: Germany Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 72: Germany 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 73: Italy Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Italy Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 75: Italy 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 76: Italy Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: Italy Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 78: Italy 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 79: UK Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: UK Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 81: UK 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 82: UK Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: UK Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 84: UK 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 85: Rest of Europe Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of Europe Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of Europe 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 88: Rest of Europe Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of Europe Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of Europe 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 91: Asia-Pacific Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 92: Asia-Pacific Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 93: Asia-Pacific 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 94: Asia-Pacific Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 95: Asia-Pacific Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 96: Asia-Pacific 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
  • Table 97: Rest of World Current & Future Analysis for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 98: Rest of World Historic Review for Gastroparesis Drugs by Disease Type - Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 99: Rest of World 15-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2012, 2020 & 2027
  • Table 100: Rest of World Current & Future Analysis for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 101: Rest of World Historic Review for Gastroparesis Drugs by Distribution Channels - Hospitals, Pharmacies, Clinics and E-Commerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 102: Rest of World 15-Year Perspective for Gastroparesis Drugs by Distribution Channels - Percentage Breakdown of Value Sales for Hospitals, Pharmacies, Clinics and E-Commerce for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll